Nektar Therapeutics (NKTR)

NASDAQ: NKTR · USD

$38.5

+0.56 (+1.5%)· Recorded snapshot

Market cap	1.3B
Revenue (ttm)	54.6M
Net income (ttm)	-157.1M
EPS (ttm)	-$6.47
Shares out	34.1M
Volume	290,492
Beta	1.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 54.6M
Net income (ttm): -157.1M
EPS (ttm): -$6.47
Market cap: 1.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-35.8

P25 n/aP50 n/aP75 n/a

ROIC-51.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NKTR indicators

Market & fundamental data

Available fields

218

Groups with data

Currency

USD

Showing 218 of 218 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000906709
Company name	Nektar Therapeutics
Country	United States
Country code	US
CUSIP number	640268306
Earnings date	2026-11-12
Earnings time	amc
Employees	63
Employees change	2
Employees growth	3.28%
Enterprise value	$767.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1990
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1994-05-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US6402683063
Last 10-K release date	2026-03-13
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2025-06-09
Last stock split type	Reverse
Market cap	$1.3B
Market cap category	Small-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$38.53
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NKTR
U.S. state	California
Website	https://www.nektar.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-16.79%
EV/Sales	13.72x
FCF / EV yield	-31.34%
FCF yield	-18.09%
Forward EV/Sales	18.16x
Forward P/S	31.46x
P/B ratio	1.43x
P/S ratio	23.77x
Price / tangible book value	1.44x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-239.32%
EBITDA margin	-238.05%
Gross margin	100%
Operating margin	-239.32%
Pretax margin	-287.72%
Profit margin	-287.84%
Profit per employee	$-2.5M
Revenue per employee	$866,492
ROA	-12.54%
ROA (5Y)	-20.76%
ROCE	-12.76%
ROE	-35.75%
ROE (5Y)	-116.6%
ROIC	-51.66%
SBC / revenue	21.95%
Tax / revenue	0.12%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Gross profit growth	-12.69%
Gross profit growth (Q)	-9.34%
Gross profit growth 3Y	-4.4%
Gross profit growth 5Y	-7.85%
Net income growth quarters	2
Net income growth years	0
Revenue growth	-27.15%
Revenue growth (Q)	-9.34%
Revenue growth (QoQ)	-6.72%
Revenue growth 10Y	-11.77%
Revenue growth 3Y	-14.63%
Revenue growth 5Y	-12.34%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-941,000
Depreciation and amortization	$693,000
EBIT	$-130.6M
EBITDA	$-130M
EPS	$-6.47
FCF per share	$-6.87
Financing cash flow	$1.1B
Free cash flow	$-234.7M
Free cash flow minus SBC	$-246.7M
Gross profit	$54.6M
Income taxes	$64,000
Investing cash flow	$-844.4M
Net borrowing	$287.5M
Net cash flow	$-3.7M
Net income	$-157.1M
Operating cash flow minus SBC	$-245.8M
Operating income	$-130.6M
Revenue	$54.6M
Stock-based compensation	$12M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.21
Book value per share	$26.46
Debt / equity	0.15
Interest coverage	-4.22
Long-term assets	$355.7M
Long-term liabilities	$121M
Net cash (debt)	$548.4M
Net cash / market cap	42.27%
Net debt / equity	-0.61
Piotroski F-Score	3
Shareholders' equity	$903.1M
Tangible book value	$903.1M
Tangible book value per share	$26.46
Total assets	$1.1B
Total cash	$684.3M
Total debt	$135.9M
Total liabilities	$192M
WACC	11.89%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.08
Current assets	$739.4M
Current liabilities	$71M
Current ratio	10.42
Net working capital	$6.8M
Quick ratio	9.71
Working capital	$668.4M
Working capital turnover	0.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-73.25%
Dividend yield	0%
Shareholder yield	-73.25%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-79.25%
10Y return CAGR	-14.55%
10Y total return	-79.25%
150-day SMA	$67.29
15Y price change	-54.03%
15Y return CAGR	-5.05%
15Y total return	-54.03%
1D price change	1.47%
1M price change	-33.18%
1M total return	-33.18%
1W price change	-2.78%
1W total return	-2.78%
1Y price change	-39.06%
1Y return CAGR	-39.08%
1Y total return	-39.06%
20-day SMA	$39.33
200-day SMA	$64.98
20Y price change	-82.6%
20Y return CAGR	-8.37%
20Y total return	-82.6%
3M price change	-46.56%
3M total return	-46.56%
3Y price change	436.51%
3Y return CAGR	75.04%
3Y total return	436.51%
50-day SMA	$57.13
50-day SMA vs 200-day SMA	50under200
52-week high	$109.00
52-week high date	2026-04-20
52-week low	$33.40
52-week low date	2026-01-30
5Y price change	-84.03%
5Y return CAGR	-30.72%
5Y total return	-84.03%
6M price change	-56.04%
6M total return	-56.04%
All-time high	$1,670.40
All-time high date	2018-03-12
All-time low	$6.19
All-time low date	2023-11-13
Average true range (ATR)	$2.43
Average volume	1.4M
Beta (1Y)	0.88
Beta (2Y)	3.56
Beta (5Y)	1.27
Change from 52-week high	-64.65%
Change from 52-week low	15.36%
Change from all-time high	-97.72%
Change from all-time low	516.09%
Change from open	2.07%
Day's gap	-0.58%
Dollar volume	$11.2M
High price	$38.56
Low price	$37.63
Monthly RSI	44.9
Open price	$37.75
Position in 52-week range	96.77%
Premarket change	0.08%
Premarket close	$37.97
Premarket price	$38.00
Previous close	$37.97
Price vs 150-day SMA	-43.33%
Price vs 20-day SMA	-3.05%
Price vs 200-day SMA	-41.32%
Price vs 50-day SMA	-33.26%
Relative volume	0.21
RSI	31.78
Sharpe ratio	-0.25
Sharpe ratio (3Y)	0.87
Sharpe ratio (5Y)	0.18
Sortino ratio	-0.34
Sortino ratio (3Y)	2.21
Sortino ratio (5Y)	0.4
Volume	290.5K
Weekly RSI	31.7
YTD price change	-9.82%
YTD total return	-9.82%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	28.3M
Float percentage	82.83%
Shares change (QoQ)	33.63%
Shares change (YoY)	73.25%
Shares held by insiders	0.37%
Shares held by institutions	89.49%
Shares outstanding	34.1M
Short % of float	24.74%
Short % of shares	20.5%
Short ratio	5.3 days

Deeper analysis on NKTR

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NKTR report

Is a complete NKTR research report available?

No complete published report is available for Nektar Therapeutics (NKTR) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Nektar Therapeutics (NKTR)

Price

Financial snapshot

Fair-value bridge

Latest news · NKTR

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NKTR indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NKTR

Frequently asked questions